ArticleTranslational pediatrics2026
Prevalence of respiratory complications in long-term survivors of childhood and adolescent cancer: a systematic review and meta-analysis.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Improved survival after childhood and adolescent cancer has led to a growing population of long-term survivors, yet the burden of late respiratory complications remains poorly quantified. In this study, the prevalence of respiratory complications in long-term survivors was quantified, and associated risk factors were identified. Methods: A systematic review and meta-analysis were performed. PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Infrastructure (CNKI), Wanfang, and China Science and Technology Journal Database (VIP) were searched from inception to December 30, 2025, for studies reporting respiratory outcomes in 5-year survivors diagnosed with malignancy before age 21 years. The primary outcome was prevalence, defined as the proportion of survivors affected at the time of assessment. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Newcastle-Ottawa Scale (NOS). Pooled prevalence was estimated using random-effects models. Results: A total of 11 studies involving 128,509 survivors were included. Study quality was generally high (NOS scores 7-9). The pooled prevalence of any respiratory complication was 35% [95% confidence interval (CI): 30-40%], though limited by extreme heterogeneity (I Conclusions: Respiratory complications affect approximately one-third of long-term survivors. Higher prevalence was associated with greater treatment intensity and longer follow-up. Lower prevalence among more recently diagnosed survivors suggests evolving treatment strategies may be reducing long-term pulmonary toxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.